Amendment to Quarterly Report Form 10 Q/A

Except as described above, this Amendment does not reflect events occurring after the date of the filing of the Original Form 10-Q or modify or update any of the other disclosures contained therein in any way. Accordingly, this Amendment should be read in conjunction with the Original Form 10-Q and the Company's other filings with the SEC. This Amendment does not reflect events that may have occurred subsequent to the filing of the Original Form 10-Q. The filing of this Amendment is not an admission that the Original Form 10-Q, when filed, included any untrue statement of a material fact or omitted to state a material fact necessary to make a statement not misleading.

1. Organization and Basis of Presentation

Revelation Biosciences, Inc. (collectively with its wholly-owned subsidiaries, the "Company" or "Revelation"), formerly known as Petra Acquisition, Inc. ("Petra"), was incorporated in Delaware on November 20, 2019. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. On August 29, 2021 Petra and Old Revelation signed an agreement and plan of merger (the "Business Combination Agreement"). On January 10, 2022 (the "Closing Date") the Company consummated its business combination, with Revelation Biosciences Sub, Inc. ("Old Revelation" or "Revelation Sub"), the Company's wholly owned subsidiary (the "Business Combination"). Since the Business Combination, the Company is a clinical-stage biopharmaceutical company and has been focused on the development and commercialization of immunologic therapeutics and diagnostics.

The Company's common stock and warrants are listed on the Nasdaq Capital Market under the symbols "REVB" and "REVBW", respectively.

Reverse Stock Split

On January 25, 2024, the Company effected the approved 1-for-30reverse stock split of our shares of common stock. Unless specifically provided otherwise herein, the share and per share information that follows in this Quarterly Report, reflects the effect of the reverse stock split.

Liquidity and Capital Resources

Going Concern

The Company has incurred recurring losses since its inception, including a net loss of $2.7million for the three months ended March 31, 2024. As of March 31, 2024, the Company had an accumulated deficit of $28.1million, a stockholders' equity of $9.5million and available cash and cash equivalents of $14.6million. The Company expects to continue to incur significant operating and net losses, as well as negative cash flows from operations, for the foreseeable future as it continues to complete all necessary product development or future commercialization efforts. The Company has never generated revenue and does not expect to generate revenue from product sales unless and until it successfully completes development and obtains regulatory approval for GEM-AKI, GEM-CKD, GEM-SSI or other product candidates, which the Company expects will not be for at least several years, if ever. The Company does not anticipate that its current cash and cash equivalents balance will be sufficient to sustain operations within one-year after the date that the Company's unaudited financial statements for March 31, 2024 were issued, which raises substantial doubt about its ability to continue as a going concern.

To continue as a going concern, the Company will need, among other things, to raise additional capital resources. The Company plans to seek additional funding through public or private equity or debt financings. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, it could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect the Company's business operations.

The unaudited consolidated financial statements for March 31, 2024, have been prepared on the basis that the Company will continue as a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability for the Company to continue as a going concern.

Basis of Presentation

The accompanying financial statements are prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). All inter-company transactions and balances have been eliminated in consolidation.

2. Summary of Significant Accounting Policies

Unaudited Interim Condensed Consolidated Financial Statements

The unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements as of December 31, 2023 and for the year ended December 31, 2023 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's financial position. The financial data and the other financial information contained in these notes to the consolidated financial statements related to the three months ended March 31, 2024 are unaudited. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim period. The consolidated financial statements and notes thereto should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended December 31, 2023 included on Form 10-K, as filed with the SEC on March 22, 2024. The accompanying consolidated balance sheet as of December 31, 2023 has been derived from the audited balance sheet at December 31, 2023 contained in the above referenced Form 10-K.

Prepaid Expenses and Other Current Assets

Property and Equipment, Net

Depreciation expense was $6,262for the three months ended March 31, 2024 and $6,263for the three months ended March 31, 2023.

Accrued Expenses

4. Commitments and Contingencies

Lease Commitments

The Company leases 2,140square feet of laboratory space located at 11011 Torreyana Road, Suite 102, San Diego, California (the "Lease"). In January 2024, the Company signed an amendment extending the Lease until November 30, 2024, with a base monthly rent equal to $5,350. The Company is required to maintain a security deposit of $5,564. The Lease contains customary default provisions, representations, warranties and covenants. In addition to rent, the Lease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises. The Company has applied the short-term lease exception as the amendment is less than twelve months. The Lease is classified as an operating lease.

Rent expense was $16,050for the three months ended March 31, 2024 and $24,991for the three months ended March 31, 2023, respectively.

Future minimum lease payments under the operating lease as of March 31, 2024 is $42,800.

Commitments

The Company enters into contracts in the normal course of business with third party service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments.

Contingencies

From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation other than described below.

Legal Proceedings

On February 18, 2022, LifeSci Capital LLC filed an action against the Company in the U.S. District Court for the Southern District of New York seeking damages in the amount of approximately $5.3million plus interest for unpaid banking and advisory fees. These fees arise under contracts which were entered into prior to the Business Combination and the Company has asserted that LifeSci Capital LLC is not entitled to the fee because it violated its responsibilities by misrepresenting to Petra the funds that would be available following the Business Combination, absent which Petra would not have entered into the Business Combination Agreement. This action remains pending as of the date of this report. $1.5million of the claim relates to deferred underwriting commissions from the Petra initial public offering, which are recorded as a current liability in the financial statements as of March 31, 2024 under deferred underwriting commissions. On December 1, 2023 a Magistrate Judge issued a report recommending summary judgment in favor of LifeSci Capital LLC. On December 15, 2023, the Company filed objections to the Magistrate's report asserting that the Magistrate Judge made factual determinations not appropriate for summary judgment and misapplied the law. The Magistrate's report is a recommendation to the trial judge who is responsible for reviewing the case de novo. Other than the deferred underwriting commissions, no liabilities are reflected in the financial statements as the amount of any additional liability cannot be determined at this time.

5. 2023 Public Offering

On February 13, 2023, the Company closed a public offering of 96,287shares of its common stock, 11,214pre-funded warrants to purchase shares of common stock with an exercise price of $0.003which did not have an expiration date (the "Class C Pre-Funded Warrants") and 6,450,000warrants to purchase up to 215,000shares of common stock with an exercise price of $160.80which expire on February 14, 2028(the "Class C Common Stock Warrants") at a combined offering price of $144.90per share of common stock and two Class C Common Stock Warrants, or $144.8970per Class C Pre-Funded Warrant and two Class C Common Stock Warrants (the "February 2023 Public Offering"). Net cash proceeds to the Company from the offering were $14.0million.

Roth Capital Partners, LLC ("Roth")was engaged by the Company to act as its exclusive placement agent for the February 2023 Public Offering. The Company paid Roth a cash fee equal to 8.0% of the gross proceeds received by the Company in the public offering, totaling $1.2million.

The shares of common stock, the shares of common stock underlying the Class C Pre-Funded Warrants and the shares of common stock underlying the Class C Common Stock Warrants were registered with the SEC on Form S-1 (File No. 333-268576) and was declared effective by the SEC on February 9, 2023.

Between February 14, 2023 and April 6, 2023, the Company received notices of cash exercise for the Class C Pre-Funded Warrants issued in connection with the February 2023 Public Offering for 11,214shares of common stock at a total purchase price of $33.64. As of March 31, 2024, there were noClass C Pre-Funded Warrants outstanding.

Using a Monte-Carlo simulation model, the Class C Common Stock Warrants were valued in the aggregate at $14.0million and included in the issuance costs of the February 2023 Public Offering and treated as a liability (see Note 10).

From March 13, 2023 to March 31, 2024, the Company received notices of alternative cashless exercises for 6,217,640Class C Common Stock Warrants issued in connection with the February 2023 Public Offering for 82,919shares of common stock. As of March 31, 2024, there were 232,360of Class C Common Stock Warrants outstanding to purchase up to 7,746shares of common stock.

As part of the February 2024 Public Offering, the exercise price of the Class C Common Stock Warrants issued in the February 2023 Public Offering was reset from $160.80to $4.53.

6. 2024 Public Offering

On February 5, 2024, the Company closed a public offering of 128,470shares of its common stock, 1,236,530pre-funded warrants to purchase shares of common stock with an exercise price of $0.0001which did not have an expiration date (the "Class D Pre-Funded Warrants") and 2,730,000warrants to purchase up to 2,730,000shares of common stock with an exercise price of $4.53which expire on February 5, 2029(the "Class D Common Stock Warrants") at a combined offering price of $4.53per share of common stock and two Class D Common Stock Warrants, or $4.5299per Class C Pre-Funded Warrant and two Class D Common Stock Warrants (the "February 2024 Public Offering"). Net cash proceeds to the Company from the offering were $5.4million.

Roth was engaged by the Company to act as its exclusive placement agent for the February 2024 Public Offering. The Company paid Roth a cash fee equal to 8.0% of the gross proceeds received by the Company in the public offering, totaling $0.5million.

The shares of common stock, the shares of common stock underlying the Class D Pre-Funded Warrants and the shares of common stock underlying the Class D Common Stock Warrants were registered with the SEC on Form S-1 (File No. 333-276232) and was declared effective by the SEC on January 31, 2024.

Between February 5, 2024 and February 13, 2024, the Company received notices of cash exercise for the Class D Pre-Funded Warrants issued in connection with the February 2024 Public Offering for 1,236,530shares of common stock at a total purchase price of $123.65. As of March 31, 2024, there were noClass D Pre-Funded Warrants outstanding.

Using the Black-Scholes option pricing model, the Class D Common Stock Warrants were valued in the aggregate at $6.3million and was included in the issuance costs of the February 2024 Public Offering and treated as equity (see Note 10).

Revelation Authorized Preferred Stock

The Certificate of Amendment of the Company authorizes up to 5,000,000shares of preferred stock, which may be issued as designated by the Board of Directors without stockholder approval. As of March 31, 2024 and as of the date of this Report, there were no shares of preferred stock issued and outstanding.

Series A Preferred Stock

On December 19, 2022, the Company closed the sale of one share of the Company's Series A Preferred Stock, par value $0.001per share, to its Chief Executive Officer for $5,000.00. The outstanding share of Series A Preferred Stock was automatically redeemed for $5,000.00on January 30, 2023 upon the effectiveness of the Certificate of Amendment implementing the reverse stock split and the increase in authorized shares of common stock of the Company.

The Company is authorized under its articles of incorporation, as amended, to issue 500,000,000shares of common stock, par value $0.001per share.

Common Stock Issuance during the year ended December 31, 2023

On February 13, 2023, the Company issued 96,287shares of its common stock in connection with the February 2023 Public Offering. The Company received net cash proceeds of $14.0million.

From February 14, 2023 to April 6, 2023, the Company issued 11,214shares of common stock in connection with notices of cash exercise for Class C Pre-Funded Warrants issued in connection with the February 2023 Public Offering with a total purchase price of $33.64.

From March 13, 2023 to June 30, 2023, the Company issued 79,521shares of common stock in connection with notices of alternative cashless exercise for the Class C Common Stock Warrants issued in connection with the February 2023 Public Offering.

On April 18, 2023, the Company issued 140shares of common stock in connection with vested Rollover RSU awards.

Common Stock Issuance during the three months ended March 31, 2024

On January 29, 2024, the Company issued 3,398shares of common stock in connection with notices of alternative cashless exercise for the Class C Common Stock Warrants issued in connection with the February 2023 Public Offering.

On January 5, 2024, the Company issued 128,470shares of its common stock in connection with the February 2024 Public Offering. The Company received net cash proceeds of $5.4million.

Between February 5, 2024 and February 13, 2024, the Company issued 1,236,530shares of common stock in connection with notices of cash exercise for Class D Pre-Funded Warrants issued in connection with the February 2024 Public Offering with a total purchase price of $123.65.

As of March 31, 2024 and December 31, 2023, 1,632,935and 264,537shares of common stock were issued and outstanding, respectively. As of March 31, 2024, nocash dividends have been declared or paid.

2021 Equity Incentive Plan

In January 2022, in connection with the Business Combination, the Board of Directors and the Company's stockholders adopted the 2021 Equity Incentive Plan (the "2021 Plan") and reserved 1,232authorized shares of common stock for issuance under the plan. The 2021 Plan is administered by the Board of Directors. Vesting periods and other restrictions for grants under the 2021 Plan are determined at the discretion of the Board of Directors. Grants to employees, officers, directors, advisors, and consultants of the Company typically vest over oneto four years. In addition, the number of shares of stock available for issuance under the 2021 Plan will be automatically increased each January 1, and began on January 1, 2022, by 10% of the aggregate number of outstanding shares of our common stock from the first day of the preceding calendar year to the first day of the current calendar year or such lesser number as determined by our board of directors. On July 14, 2023 at the Company's 2023 Annual Meeting of Stockholders, an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the Plan to 21,623was approved.

Under the 2021 Plan, stock options and stock appreciation rights are granted at exercise prices determined by the Board of Directors which cannot be less than 100% of the estimated fair market value of the common stock on the grant date. Incentive stock options granted to any stockholders holding 10% or more of the Company's equity cannot be granted with an exercise price of less than 110% of the estimated fair market value of the common stock on the grant date and such options are not exercisable after five yearsfrom the grant date.

As of March 31, 2024, there were 20,466shares available for future grants under the 2021 Plan.

Restricted Stock Units

At the Closing Date of the Business Combination, all Revelation Sub RSU award holders received a Rollover RSU award in exchange for each RSU award of Revelation Sub that vest in accordance with the original terms of the award. The Company determined this to be a Type I modification but did not record any incremental stock-based compensation expense since the fair value of the modified awards immediately after the modification was not greater than the fair value of the original awards immediately before the modification.

The Rollover RSU awards have time-based and milestone-based vesting conditions. Under time-based vesting conditions, the Rollover RSU awards vest quarterly over one-yearfor grants to the Board of Directorsand quarterly over four yearsor 25% on the one-year anniversary and the remainder vesting monthly thereafter for grants to officers, employees and consultants.The milestone-based vesting conditions vested on the Closing Date of the Business Combination.

As of March 31, 2024 and December 31, 2023, the Company has a total of 94Rollover RSU awards for shares of common stock outstanding, respectively. As of March 31, 2024, 61Rollover RSU awards have fully vested but are unissued and no Rollover RSU awards have been forfeited. As of March 31, 2024, 94Rollover RSU awards will vest and be issued over the next 0.9years. Each Rollover RSU award converts to one share of common stock.

Stock Options

The Company has granted stock options which(i) vest fully on the date of grant; (ii) vest 25% on the one-year anniversary of the grant date or the employees hiring date, with the remainder vesting quarterly thereafter; or (iii) vest quarterly over one-year, for grants to Board of Directors, officers and employees.Stock options have a maximum term of 3or 10 years.

For the three months ended March 31, 2024, the weighted-average Black-Scholes value per stock option was $314.03.The fair value of the stock options was estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:

Expected volatility is based on the historical volatility of shares of the Company's common stock. In determining the expected term of stock options, the Company uses the "simplified" method. Under this method, the expected term is presumed to be the midpoint between the average vesting date and the end of the contractual term. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the stock options in effect at the time of the grants. The dividend yield assumption is based on the expectation of no future dividend payments by the Company. In addition to assumptions used in the Black-Scholes model, the Company reduces stock-based compensation expense based on actual forfeitures in the period that each forfeiture occurs.

Stock-Based Compensation Expense

As of March 31, 2024, there was $82,621and $59,564of unrecognized stock-based compensation expense related to Rollover RSU awards and stock options, respectively. The unrecognized stock-based compensation expense is expected to be recognized over a period of 0.9years and 1.9years for Rollover RSU's and stock options, respectively.

10. Warrants

Public Warrants

In connection with Petra's initial public offering ("IPO"), Petra issued and has outstanding as of March 31, 2024 10,511,597Public Warrants to purchase an aggregate of 10,012shares of common stock with an exercise price of $12,075.00per share which expire on January 10, 2027 (the "Public Warrants"). The Public Warrants trade on the Nasdaq Capital Market under the ticker symbol REVBW.

The Company may redeem the Public Warrants at a price of $0.01per Public Warrant upon not less than 30 days' prior written notice of redemption if, and only if, the reported last sale price of the Company's common stock equals or exceeds $18,900.00per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the notice of redemption to the Public Warrant holders; and if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying the Public Warrants. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a "cashless basis," as described in the warrant agreement.

Rollover Warrants

Prior to the Merger, Revelation Sub issued warrants to a placement agent to purchase up to 157shares of common stock with an exercise price of $2,816.92per share which expire on January 31, 2027, valued on the issuance date in the aggregate at $326,675. At the Closing Date of the Business Combination, all warrant holders received a Rollover Warrant, which was exercisable in accordance with its original issuance.

On February 2, 2022, the Company received a notice of cash exercise for the Company's Rollover Warrants for 2shares of common stock at a purchase price of $5,073. As of March 31, 2024, there were 155Rollover Warrants remaining to be exercised or exchanged.

Class A Common Stock Warrants

In connection with the closing of a private placement on January 25, 2022 ("PIPE Investment"), the Company issued warrants to an institutional investor to purchase up to 2,464shares of common stock at an exercise price of $3,454.50per share (the "Class A Common Stock Warrants"), valued on the PIPE Investment purchase date in the aggregate at $3.6million and included in the issuance costs of the PIPE Investment and treated as equity. The warrants were exercisable immediately upon issuance, provide for a cash or cashless exercise right and expire on July 25, 2027.

Class A Placement Agent Common Stock Warrants

In connection with the PIPE Investment, the Company issued warrants to Roth to purchase an aggregate of 345shares of common stock at an exercise price of $3,454.50per share (the "Class A Placement Agent Common Stock Warrants"), valued on the PIPE Investment purchase date in the aggregate at $0.5million and included in the issuance costs of the PIPE Investment and treated as equity. The warrants were exercisable immediately upon issuance, provide for a cash or cashless exercise right and expire on July 25, 2027.

Class B Common Stock Warrants

In connection with closing of a public offering on July 28, 2022 ("the July 2022 Public Offering"), the Company issued and has outstanding 8,333,334warrants to purchase an aggregate of 7,937shares of common stock at an exercise price of $630.00per share(the "Class B Common Stock Warrants"), valued on the public offering purchase date in the aggregate at $4.5million and included in the issuance costs of the public offering and treated as equity. The warrants were exercisable immediately upon issuance, provide for a cash or cashless exercise right and expire on July 28, 2027.

Class B Placement Agent Common Stock Warrants

In connection with the July 2022 Public Offering, the Company issued warrants to the Placement Agent to purchase up to 556shares of common stock at an exercise price of $787.50per share (the "Class B Placement Agent Common Stock Warrants"), valued on the public offering purchase date in the aggregate at $0.3million and included in the issuance costs of the public offering and treated as equity. The warrants were exercisable immediately upon issuance, provide for a cash or cashless exercise right and expire on July 25, 2027.

Class C Pre-Funded Warrants

In connection with the February 2023 Public Offering, the Company issued pre-funded warrants to purchase up to 11,214shares of common stock at an exercise price of $0.003per share. Between February 14, 2023 and April 6, 2023, the Company received notices of cash exercise for the Class C Pre-Funded Warrants issued in connection with the February 2023 Public Offering for 336,400shares of common stock at a total purchase price of $33.64. As of March 31, 2024, there were noClass C Pre-Funded Warrants outstanding.

Class C Common Stock Warrants

In connection with the February 2023 Public Offering, the Company issued 6,450,000warrants to purchase up to 215,000shares of common stock at anexercise price of $160.80per share, valued on the public offering purchase date in the aggregate at $13,996,500and included in the issuance costs of the public offering and treated as a liability . The warrants were exercisable immediately upon issuance, provide for a cash, cashless exercise right or an alternative cashless exercise right for 0.4shares of common stock per Class C Common Stock Warrant and expire on February 14, 2028.

The Company evaluated the Class C Common Stock Warrants under ASC 815-40, Derivatives and Hedging-Contracts in Entity's Own Equity ("ASC 815-40") and concluded that they do not meet the criteria to be classified in stockholders' equity and accounted for the Class C Common Stock Warrants as current liabilities.

The Company concluded that the multiplier of 0.4shares of common stock per Class C Common Stock Warrant used in the alternative cashless exercise precludes the Class C Common Stock Warrants from being considered indexed to the Company's stock. The Company recorded the Class C Common Stock Warrants as current liabilities on the balance sheet at fair value, with subsequent changes in their respective fair values recognized in the consolidated statements of operations at each reporting date. Estimating fair values of liability-classified financial instruments requires the development of estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of the Company's common stock. Because liability-classified financial instruments are initially and subsequently carried at fair value, the Company's financial results will reflect the volatility in these estimate and assumption changes. Changes in fair value are recognized as a component of other (expense) income in the consolidated statements of operations.

At the date of issuance, the Company valued the Class C Common Stock Warrants using a Monte-Carlo simulation model with a fair value of $14.0million.

As of March 31, 2024, the Company received notices of alternative cashless exercises for 6,217,640Class C Common Stock Warrants issued in connection with the February 2023 Public Offering for 82,919shares of common stock.

As of March 31, 2024, the Company re-valued 232,360outstanding Class C Common Stock Warrants to purchase up to 7,746shares of common stock using a Monte-Carlo simulation model with a fair value of $15,260.0million. For the three months ended March 31, 2024, the gain of $0.1million, respectively, resulting from the change in the fair value of the liability for the unexercised warrants was recorded as a change in fair value of the warrant liability in the accompanying consolidated statements of operations for the three months ended March 31, 2024.

As part of the February 2024 Public Offering, the exercise price of the Class C Common Stock Warrants issued in the February 2023 Public Offering was reset from $160.80to $4.53.

Class D Pre-Funded Warrants

In connection with the February 2024 Public Offering, the Company issued pre-funded warrants to purchase up to 1,236,530shares of common stock at an exercise price of $0.0001per share. Between February 5, 2024 and February 13, 2024, the Company received notices of cash exercise for the Class D Pre-Funded Warrants issued in connection with the February 2024 Public Offering for 1,236,530shares of common stock at a total purchase price of $123.65. As of March 31, 2024, there were noClass D Pre-Funded Warrants outstanding.

Class D Common Stock Warrants

In connection with the February 2024 Public Offering, the Company issued and has outstanding 2,730,000warrants shares of common stock at an exercise price of $4.53per share, valued on the public offering purchase date in the aggregate at $6.3million and included in the issuance costs of the public offering and treated as equity. The warrants were exercisable immediately upon issuance, provide for a cash or cashless exercise right and expire on February 5, 2029.

11. Income Taxes

The quarterly provision for or benefit from income taxes is computed based upon the estimated annual effective tax rate and the year-to-date pre-tax (loss) income and other comprehensive (loss) income. The Company did not record a provision or benefit for income taxes during the three months ended March 31, 2024 and 2023, respectively.

For the three months ended March 31, 2024 and 2023, the Company recorded non-taxable income of $0.1million and $7.7million, respectively, related to a change in the fair value of a warrant liability. The Company incurred taxable losses in 2023 and projects further taxable losses for 2024. The Company did not record a benefit from income taxes because, based on evidence involving its ability to realize its deferred tax assets, the Company recorded a full valuation allowance against its deferred tax assets.

14. Subsequent Events

On April 26, 2024 the Company entered into a confidential settlement agreement with A-IR Clinical Research Ltd. ("A-IR") for a previously filed claim against the Company in the High Court of Justice, in the Business and Property Courts of England and Wales and is included in other (expense) income in the accompanying consolidated statements of operations.